This study aims to characterize the epidemiology, clinicopathologic features, and survival outcomes of Chinese patients with PTCL; to develop and validate prognostic models to this population; to compare the real-world effectiveness and safety of alternative therapeutic strategies; to elucidate molecular mechanisms underlying treatment resistance and relapse; to identify actionable targets and predictive biomarkers.
Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms).
Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024.
Cohort B: Patients newly diagnosed from October 2025 onward.
Availability of basic diagnostic and treatment records .
Indeterminate diagnosis or missing pathology report.
Patients diagnosed at an outside institution who did not receive their primary treatment and follow-up at a participating center.
Diagnoses of NK/T-cell lymphoma or primary cutaneous T-cell lymphomas.
Fudan University
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Collaborator